Paget's disease of bone treated with a five day course of oral tiludronate

Article Abstract:

Tiludronate may be an effective and safe treatment for patients suffering from Paget's disease of bone. Paget's disease of bone is a skeletal disease characterized by thickening and softening of the bones. Among 15 patients suffering from Paget's disease of the bone, four were treated with 600 milligrams (mg) per day of tiludronate, five received 800 mg per day and six received 1,200 mg daily over a five-day period. Patients in all three treatment groups experienced a decrease in their blood levels of alkaline phosphatases, a group of enzymes involved in bone resorption. All the patients experienced a decrease in their urinary hydroxyproline/creatinine ratio, especially those treated with 1,200 mg of tiludronate per day. Half the patients treated with 1,200 mg experienced some gastrointestinal upset such as mild diarrhea, but those treated with lower doses did not have these side effects.

Health aspects

---

Changes in bone mineral density in patients with Paget's disease treated with risedronate

Article Abstract:

Risedronate treatment appears to significantly increase overall bone mineral density (BMD) but particularly diseased bone areas of patients with Paget's disease. BMD measurements were taken of the whole body and selected diseased sites of 20 patients with Paget's disease before and after 11 months of treatment with risedronate. The largest increases in BMD were seen in diseased vertebrae. Decreases in bone metabolism benchmarks coincided with increases in BMD measurements in diseased bone. There was no evidence that bone density had transferred from healthy to diseased bone.

Bones, Bone density

---

Tiludronate for Paget's disease of bone

Article Abstract:

The Paget's disease of bone bisphosphonate treatment, Tiludronate, sold as Skelid by Sanofi, has been given FDA approval. It seems to be more effective than either a placebo or etidronate in relieving bone pain, lowering blood levels of alkaline phosphatase,and in reducing bone loss. Side effects are possibly more than with etidronate and may include abdominal pain, nausea, diarrhea, and vomiting. It is more expensive than other treatments and other comparative trials have not yet been done.

Product/Service Evaluation, Skelid (Medication)

Similar abstracts:

• Abstracts: Corneal disease. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation
• Abstracts: Adapting the chronic disease model in the treatment of dually diagnosed patients. Organizational change required for paradigmatic shift in addiction treatment
• Abstracts: Cheers! The use of maggots as a new treatment in the community
• Abstracts: Dissemination of printed information for patients: a qualitative study of general practices. Whose neighbourhood? Whose quality of life? Developing a new agenda for children's health in urban settings
• Abstracts: Loss adjusters. Someone to watch over you. Safety net

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.